Literature DB >> 8625210

Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel.

V G Schweitzer1, G J Juillard, C L Bajada, R G Parker.   

Abstract

BACKGROUND: Radiation recall refers to a tissue reaction produced by a chemotherapeutic agent in a previously irradiated field that would not occur in a nonirradiated field. A number of agents have been reported to cause radiation recall. Recently, there have been case reports of recall dermatitis from paclitaxel treatment.
METHODS: A patient with metastatic lung cancer received palliative radiation to her mediastinum and ribs. Because of disease progression, she subsequently received paclitaxel.
RESULTS: After paclitaxel administration, the patient became acutely dyspneic. A subsequent chest X-ray revealed a parenchymal opacity in a region that corresponded with the patient's radiation portal. She also developed a severe skin reaction in the previously treated electron field.
CONCLUSIONS: This is one of few reported cases of recall dermatitis from paclitaxel and is also suggestive of recall pneumonitis, a phenomenon previously unreported to the authors' knowledge. Given paclitaxel's ability to function as a radiosensitizer, this response is not unexpected. As the frequency of paclitaxel administration increases, its potential as a radiation sensitizer and radiation recall should be considered.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8625210     DOI: 10.1002/1097-0142(19950915)76:6<1069::aid-cncr2820760623>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  29 in total

1.  Radiation recall dermatitis with azithromycin.

Authors:  O Vujovic
Journal:  Curr Oncol       Date:  2010-08       Impact factor: 3.677

2.  Pemetrexed-induced radiation recall dermatitis in a patient with lung adenocarcinoma: case report and literature review.

Authors:  Jin Ge; Vivek Verma; Andrew Hollander; Corey Langer; Charles B Simone
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

3.  Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors.

Authors:  Masahiro Tsuboi; Thierry Le Chevalier
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

4.  Exacerbation of radiation fibrosis with erlotinib: another pattern of radiation recall phenomenon.

Authors:  Hiroaki Arakawa; Takeshi Johkoh; Fumikazu Sakai; Masahiko Kusumoto; Osamu Hataji; Osamu Taguchi
Journal:  Jpn J Radiol       Date:  2011-09-17       Impact factor: 2.374

5.  Sequential adjuvant chemoradiotherapy-induced diffuse alveolar haemorrhage in a patient with breast cancer successfully treated with corticosteroid plus recombinant human soluble thrombomodulin.

Authors:  Takamasa Kitajima; Satoshi Marumo; Yurina Maeshima; Motonari Fukui
Journal:  BMJ Case Rep       Date:  2016-10-28

6.  Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome--recall following different chemotherapy agents.

Authors:  Yuk Fung Hui; Francis J Giles; Jorge E Cortes
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850

7.  Radiation recall dermatitis with soft tissue necrosis following pemetrexed therapy: a case report.

Authors:  Christian Spirig; Aurelius Omlin; Giannicola D'Addario; Klaus-Dieter Loske; Philipp Esenwein; Jan Henning Geismar; Thomas Ruhstaller
Journal:  J Med Case Rep       Date:  2009-11-02

Review 8.  Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).

Authors:  Christopher J Anker; Kenneth F Grossmann; Michael B Atkins; Gita Suneja; Ahmad A Tarhini; John M Kirkwood
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-06-01       Impact factor: 7.038

Review 9.  Management of normal tissue toxicity associated with chemoradiation (primary skin, esophagus, and lung).

Authors:  Victor Y Yazbeck; Liza Villaruz; Marsha Haley; Mark A Socinski
Journal:  Cancer J       Date:  2013 May-Jun       Impact factor: 3.360

Review 10.  Understanding the mechanisms of drug-associated interstitial lung disease.

Authors:  T Higenbottam; K Kuwano; B Nemery; Y Fujita
Journal:  Br J Cancer       Date:  2004-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.